Summary:
In adults with type 2 diabetes and cardiovascular risk factors, once-weekly GLP-1 receptor agonist exenatide significantly reduced cardiovascular risk, including hospitalizations for heart failure (hHF) and myocardial infarctions (MI) compared to control treatments, despite no mediation effects observed from conventional cardiovascular (CV) risk factor changes within one year,
though it was associated with mild gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes and increased cardiovascular risk factors. |
| Intervention | Once-weekly GLP-1 receptor agonist exenatide. |
| Comparison | Control treatments (other conventional therapies or no GLP-1 receptor agonist treatment). |
| Outcome | Exenatide significantly reduced adverse cardiovascular outcomes, such as hospitalizations for heart failure (hHF) and myocardial infarctions (MI), compared to the control treatments. Changes in conventional CV risk factors (e.g., HbA1c, weight, blood pressure) within one year did not mediate the all-cause mortality (ACM) risk reduction. Mild gastrointestinal side effects were observed. |
Source: Ruth L Coleman, et al. “Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.” Read article here.
